Massachusetts Senate rejects budget amendment curbing drug pricing requirements

The Massachusetts Senate has rejected an attempt to water down a drug price transparency bill, rebuffing an amendment to pending budget legislation. Wednesday’s development is leaving the biotech industry in the state uneasy, with the head of MassBio saying it could threaten the development of new therapies.

Amendment 654 would have limited transparency requirements to drugs in which supplemental rebates weren’t negotiated between manufactures and the state. ...